SUNNYVALE, Calif., Sept. 15, 2015
ClearLight Diagnostics, a developer of new tools and technologies for the analysis and imaging of tissue samples, announced today that it has signed an exclusive, worldwide license agreement with Stanford University for the intellectual property rights covering inventions relating to tissue processing and imaging. The licensed technologies involve CLARITY, a tissue “clarification” method that renders the tissue optically transparent, and COLM (CLARITY Optimized Light-sheet Microscopy), a new optics system for accelerating image collection from clarified samples. ClearLight is initially funded by a syndicate created by Wiegers Capital Partners LLC, and plans to commercialize products and services based on the licensed technologies.
“We are excited by the prospect of further developing the CLARITY and COLM technologies,” said Sarah McCurdy, Chief Executive Officer of ClearLight Diagnostics. “Our development efforts will ultimately impact the lives of many patients through the creation of new tools and services for diagnosing diseases and finding new treatments.”
About ClearLight Diagnostics
ClearLight Diagnostics is a technology development company focused on the discovery, development and commercialization of innovative technologies to significantly improve the diagnosis and treatment of a wide range of diseases. The company is developing a groundbreaking tissue processing and imaging platform that allows for the three-dimensional investigation of molecular and structural information within specific tissues. The CLARITY method is built on sophisticated chemical treatments of tissues to make them fully transparent and includes COLM, a powerful imaging platform that allows for visualization of labeled tissue elements, cells and connections within tissue blocks.
For immediate release: ClearLight Diagnostics, LLC.